Vyvanse is a successor to Adderall XR for attention deficit hyperactivity disorder. CRH Plc (CRH ID) fell 15 cents, or 0.8 percent, to 25.93 euros. ...
The broker said that 52 per cent of high prescribers saw no difference between Vyvanse and Shire’s older drug Adderall XR, whose patent is due to expire ...
"Vyvanse is not a simple switch from Adderall XR but captures competitors' market share, which should reduce the impact of Adderall (going generic) in April ...
Vyvanse is a successor to Adderall XR for attention deficit hyperactivity disorder. Thomas Cook Group Plc (TCG LN), Europe's second-biggest tour operator, ...
Dani Saurymper downgraded the stock to "Neutral" from "Buy," and said that doctors do not find Vyvanse to be superior to Adderall XR, Shire (nasdaq: SHPGY ...
"This not only entails converting patients from Adderall XR but also the more significant patient population currently using alternative therapies. ...
Vyvanse is designed to replace the blockbuster Adderall XR, whose patent expires next year. Meanwhile, with little economic or earnings announcements to ...
Vyvanse is designed to replace the blockbuster Adderall XR, whose patent expires next year. BAE Systems slipped on a report that two of its flagship ...
In a client note, Cacciatore said about 19 percent of Shire's Adderall XR users have switched to Vyvanse. He thinks that number will rise to about 40 ...
Vyvanse is a successor to Adderall XR for attention deficit hyperactivity disorder. Thomas Cook Group Plc (TCG LN), Europe's second-biggest tour operator, ...